Roggwil, October 25, 2021 – Based on patient feedback, we can report that the tinniwell with its patented heat therapy has a very good effect on migraine patients. 30 – 60 minutes before the aura occurs, the person concerned has treated their tinnitus with the tinniwell. The patients report that in these cases the aura was very mild or did not occur at all. Since about 10% of the population suffers from migraines, this is a possible significant expansion of the tinniwell patient group.
The management of Resaphene would now like to have a clinical user observation carried out via this possible extension of the therapy options. The market is currently being explored with regard to possible cooperation partners.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668